Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Animal Healthcare Market – Insights
Animal healthcare focuses on effective animal health management through diagnosis and treatment of various diseases in animals.
The global animal healthcare market is estimated to account for US$ 61,168.31 Mn in terms of value by the end of 2027
Global Animal Healthcare Market: Drivers
Increasing consumption of meat, milk and other animal byproducts is expected to boost growth of the global animal healthcare market over the forecast period. For instance, the USDA National Agricultural Statistics Service (NASS) estimated November 2019 U.S. milk production at 17.440 billion pounds, 0.5 percent higher than November 2018.
Moreover, increasing prevalence of foodborne and zoonotic diseases is also expected to propel growth of the market. For instance, according to May 2019 report of the Centers of Disease Control and Prevention (CDC), salmonella infection (salmonellosis) causes approximately 1.2 million illnesses and 450 deaths annually, in the U.S. and in 2018, there were 18 reported outbreaks, 15 of which were linked to food.
North America held dominant position in the global animal healthcare market in 2019, accounting for 33.1% share in terms of value, followed by Europe and Asia Pacific, respectively
Figure 1. Global Animal Healthcare Market Share (%), by Region, 2019
Source: Coherent Market Insights Analysis (2020)
Global Animal Healthcare Market: Restraints
A lack of surveillance and diagnostics for zoonotic diseases in developing economies is expected to hinder growth of the global animal healthcare market.
Moreover, stringent regulations over use of antibiotics in animal feed is also expected to limit growth of the market. For instance, in the U.S. state of California Senate Bill 27—known as SB 27—aims to minimize the feeding of antibiotics to animals and it prohibits the use of antibiotics “solely for purposes of promoting weight gain or improving feed efficiency.”
The Production Animal segment was valued at US$ 26,374.5 Mn in 2019 and is forecast to reach a value of US$ 39,159.8 Mn by 2027 at a CAGR of 5.1% between 2019 and 2027
Market Trends/Key Takeaways
In the U.S., beef export has declined, which is expected to hinder growth of the market. For instance, according to the USDA National Agricultural Statistics Service (NASS), in November 2019, beef exports from the U.S. totaled 245 million pounds, 21 million pounds below the November 2018 total.
Asia Pacific is expected to witness significant growth in the market, owing to increasing production of milk. For instance, according to the UN's Food and Agriculture Organization (FAO), in 2018, India produced 186 million tons of milk, which was 22% of that year's global total milk production of 843 million tons.
In order to reduce the use of antibiotics as growth promoters in animals, the Danish Veterinary and Food Administration (DVFA) restricted the use of fluoroquinolones (banned) and cephalosporins in 2002. In 2010, an industrial voluntary ban (Sweden, France and Denmark) on the use of cephalosporins was implemented for a 2-year period, and a Yellow Card initiative was implemented in Denmark, targeting the largest consumers of antibiotics in the swine production industry. As a result, the consumption of antibiotics from January 2011 to June 2011 was 25 % lower compared to the same period the previous year.
2005: FDA banned the use of Baytril – a fluoroquinolone antibiotic – also known as enrofloxacin – in chicken and turkey. The antibiotic leads to the emergence of antibiotic resistant bacteria such as Campylobacter in humans, as its chemical composition is similar to that of Cipro – a human antibiotic – which is a common prescription drug to treat foodborne illnesses in humans.
2012: Maryland banned the usage of arsenic-based drugs in chicken feed. However, it is used across other states in the U.S. The drug received FDA approval as its arsenic content is within safe limits for human consumption.
2014: The FDA directed 26 major pharmaceutical companies in the U.S. to cease production of weight-gain drugs for animals by December 2016. It further directed the companies to stop OTC sales of antimicrobials such as Roxarsone (sold under the brand 3-Nitro) administered to livestock through feed and water, which are also used in human medicine. The objective of this move is to reduce health risks associated with the consumption of antimicrobial treated meat products.
Ractopamine hydrochloride – a growth promoter drug – is banned in Europe and 160 other countries such as China, Taiwan, Russia, India, Turkey, Iran, Egypt, Kenya and Zimbabwe. However, its use is permitted in the U.S., Brazil and Canada to increase muscle production in swine, turkey and cattle. Since December 2012, meat imports in Russia from countries such as the U.S. is subject to ractopamine-free certification.
GROUP I. Drugs with No Allowable Extra-label Uses in Any Food-producing Animal Species
GLYCOPEPTIDES — all agents, including VANCOMYCIN
NITROIMIDAZOLES-all agents, including DIMETRIDAZOLE, IPRONIDAZOLE, METRONIDAZOLE and others
NITROFURANS — all agents, including FURAZOLIDINE, NITROFURAZONE and others
GROUP III. Drugs with Special Restrictions for Grade "A" Dairy Operations
- Grade A Pasteurized Milk Ordinance
- NON-MEDICAL GRADE DIMETHYLSULFOXIDE (DMSO) — no use or storage allowable
- DIPYRONE — no use allowable
- COLLOIDAL SILVER — no use or storage allowable
- SYSTEMICALLY–ACTING DRUGS THAT ARE APPLIED TOPICALLY (including Fenthion, Famphur and Xylene, Phosmet, Levamisole and all ivermectins and avermectins — no use allowable
GROUP II. Drugs with Restricted Extra-Label Uses in Food-Producing Animal Species
- ADAMANTANE & NEURAMINIDASE INHIBITORS in all poultry, including ducks
– these agents are approved for treatment or prevention of influenza A
- CEPHALOSPORIN–CLASS ANTIBIOTICS except CEPHAPIRIN in all classes of cattle, chickens, pigs and turkeys
– ELDU restrictions apply to ALL PRODUCTION CLASSES OF MAJOR FOOD-ANIMAL SPECIES.
- 1) No ELDU for purpose of disease prevention
- 2) No ELDU that involves unapproved dose, treatment duration, frequency or administration route
- 3) Agent must be approved for that species and production class
– ELDU restrictions DO NOT APPLY to minor–use food animal species.
- GENTIAN VIOLET — prohibited for use in food or feed of food-producing animal species
- INDEXED DRUGS — some exceptions for minor-use species
- PHENYLBUTAZONE — in female dairy cattle (20 months of age or older)
- SULFONAMIDE–CLASS ANTIBIOTICS — in lactating dairy cattle– approved uses are allowed for Sulfadimethoxine, Sulfabromomethazine and Sulfaethoxypyridazine
Global Animal Healthcare Market: Competitive Landscape
Major players operating in the global animal healthcare market include, Bayer AG, Boehringer Ingelheim GmbH, Cargill, Inc., Ceva Santé Animale, Eli Lilly and Company, Koninklijke DSM N.V., Merck & Co., Inc., Novartis AG, Nutreco N.V., Sanofi S.A., SeQuent Scientific Ltd., Virbac S.A., Vétoquinol S.A., and Zoetis Inc.
Global Animal Healthcare Market: Key Developments
Major players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in 2018, Boehringer Ingelheim Animal Health collaborated with Kamraan Veterinary Medicine Co. Group, a veterinary medicine wholesaler and retailer in U.A.E, for marketing veterinary medicines.
Major players in the market are also focused on launching new products to expand their product portfolio. For instance, in March 2020, Kinetic Vet, an animal health company, launched ArmourGuard RTU, an EPA-approved spray-on antimicrobial biosecurity solution that provides continual antimicrobial activity against microorganisms for up to 90 days.